“Dr. Sunita Singh is a Transplant Nephrologist in the Division of Nephrology at the Toronto General Hospital with additional training in diabetes care in transplant recipients and pancreas transplantation as a treatment option for patients with Type 1 diabetes.
In collaboration with Dr. David Cherney, Dr. Singh is currently a site investigator/Co-Investigator at UHN for two clinical trials: 1) DAPA CKD: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease and 2) A double-blind, placebo controlled, cross-over renal mechanistic trial to assess the effect of adding empagliflozin versus placebo on renal hyperfiltration in patients with type 1 diabetes on a background of the angiotensin converting enzyme inhibitor (ACEi) Ramipril: BETWEEN study.”
“Dr. Singh has a research interest in Pancreas Transplantation. She is currently a Co-Investigator (PI: Dr. Cherney, Co-I: Dr. Kim, Dr. Cattral) on a pilot study evaluating the impact of pancreas transplantation on the complications of Type 1 diabetes (BBDC Sun Life Financial Pilot and Feasibility Grant) and has published clinical outcomes research in patients with type 1 diabetes with pancreatic transplants.
Dr. Singh also has an interest in understanding the pathogenesis of recurrent diabetic kidney disease (DKD) in the kidney allograft and therapies for DKD in the transplant population. Her working group has published their experience describing the safety and efficacy of SGLT2 inhibitors in a group of kidney and kidney-pancreas transplant recipients.”